We exploit dislocations in markets and unlock value from complex situations using a Get Rich and Stay Rich strategy. This strategy has given rise to returns over 23 years of 28% p.a. Net IRR
Reg UK (REG), the provider of a range of data analytics and risk management solutions to insurance intermediaries globally, has completed a GBP2.4 million funding round.
The additional capital will enable further investment in the platform, people and systems to support the Company’s accelerating growth trajectory both in the UK and globally. As part of the fundraising round, Disruptive Capital Finance followed on its existing capital with additional equity capital while Shawbrook arranged a debt facility.
Disruptive Capital Finance represents the private equity investment vehicle and family office of the Truell family, in which they hold the vast majority of their assets. Edi Truell’s track record stands at a 28 per cent net IRR pa across all 51 platform deals over the last 25 years. With positive returns in every three, five and ten year rolling period it has demonstrated an acute sense of risk management as well as buying, building and transforming private companies to become global market leaders.
REG aspires to become the go-to solution for Insurers and Intermediaries looking to simplify compliance and management processes between insurers, brokers and customers. With clients across the country and a number of international markets, including ageas, PIB Group, Lloyds and GRP, REG continues to demonstrate its outstanding growth potential as part of the UK InsurTech sector.
The London-based business now employs 35 people and continues to disrupt the insurance market place by accelerating due diligence processes and enhancing ongoing risk management through advanced data analytics and monitoring tools.
Edi Truell, Founder, Disruptive Capital Finance, says: “REG has a compelling and market leading position in a fast growing sector. We are delighted with its progress since our initial investment and we look forward to actively supporting its continued success.”
Michael Phair, CEO, REG (UK) Ltd, says: “This facility not only provides scope for further growth but is also a validation of what we’ve already achieved. Whilst venture debt isn’t readily available on the high street or from our main bankers, fast growth businesses like REG, with high levels of annual reoccurring revenue need this type of support to scale-up and succeed – particularly internationally.”
02/11/2023
Global Interconnection Group (GIG) is delighted to have signed an exclusivity agreement with a major UK energy company to explore collaboration on the Atlantic SuperConnection interconnection project.
Click the link in the title to read more
02/11/2023
Pension SuperFund Capital, which oversees UK commercial pension consolidator Pension SuperFund, has reached an agreement to acquire the parent group of Options Pensions, STM Group, for £35.6m.
The purchase was made through the Pension SuperFund Capital acquisition arm Bidco. It is expected that if the full value is delivered by the deferred consideration units (DCU), the acquisition value could rise to £39.8m, it was announced this morning.
The scheme shareholders will also be entitled to receive 60 pence per share in cash, rising to 67 pence per share if full value is delivered by DCU.
We’re glad to see that you may be inspiring others with our journalistic content. We ask that you copy our content for personal use only, so as not to violate our Terms and Conditions. Otherwise, ask about our group memberships via lorenzo.passarella@ipe.com. Text copied from: https://www.ipe.com/news/pension-superfund-capital-acquires-stm-group-for-356m/10069392.article
02/11/2023
ViroCell’s manufacturing operations are housed within Great Ormond Street Hospital’s state-of-the-art GMP accredited unit for manufacturing cell and gene therapies, the Zayed Centre for Research
London, UK and New York, US, 1 November 2023 – ViroCell Biologics (“ViroCell” or the “Company”), a specialist contract development and manufacturing organisation (“CDMO”) for cell and gene therapy (CGT) clinical trials, announces that the Company is now able to manufacture and globally export viral vectors from Great Ormond Street Hospital’s (GOSH) state-of-the-art manufacturing facility, the Zayed Centre for Research, for use in clinical trials. This follows the grant of a Manufacturer’s Authorisation License (MIA) to GOSH to manufacture viral vectors by the UK’s Medicines and Healthcare products Regulatory Agency’s (MHRA).
Read more by clicking the title link
02/06/2023
An experienced team of Private Markets analytics specialists supporting the industry renowned work of Professor Oliver Gottschalg of HEC Paris is delighted to announce the launch of Gottschalg Analytics as an independent second-generation provider of performance intelligence services for the Private Markets.
30/03/2023
Pension Insurance Corporation Group Limited1 ('PICG' or the 'Company'), ultimate parent company of Pension Insurance Corporation plc ('PIC'), the specialist insurer of UK defined benefit pension schemes, today announces its final results for the 12 months to 31 December 2022.
13/03/2023
DCAC announced proposals to form the Advanced Cables Business Combination in the press release issued by the Company on 20th February 2023. The DCAC Board has now decided to expedite the proposals, and DCAC has therefore agreed an exclusive option to acquire the holding company of Advanced Cables, Global InterConnection Group SA (“GIG” or the “Target”). Besides Advanced Cables, GIG is also the holding company of ASC Energy Limited. It is intended that DCAC will be renamed "Global InterConnection Group Limited" on completion of the Business Combination.